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Abstract
Objective—This study examined symptom-based subgroups of metastatic breast cancer (MBC) 
patients and the extent to which they differed across key constructs of Acceptance and 
Commitment Therapy (ACT).
Methods—Eighty women with MBC completed self-report surveys assessing ten common 
symptoms and several ACT variables (i.e., activity engagement, psychological inflexibility, value 
obstruction, and value progress) during a single time point.
Results—A cluster analysis yielded three patient subgroups: low symptoms, low-moderate 
symptoms, and moderate-high symptoms. Relative to the subgroup with low symptoms, the other 
subgroups reported less activity engagement. In addition, compared to patients with low 
symptoms, the subgroup with moderate-high symptoms reported greater psychological 
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inflexibility (i.e., avoidance of unwanted internal experiences) and greater difficulty living 
consistently with their values.
Conclusions—Women with MBC show heterogeneity in their symptom profiles, and those with 
higher symptom burden are more likely to disengage from valued activities and avoid unwanted 
experiences (e.g., thoughts, feelings, bodily sensations). Findings are largely consistent with the 
ACT model and provide strong justification for testing ACT to address symptom interference in 
MBC patients.
Keywords
metastatic breast cancer; oncology; symptoms; activity engagement; acceptance and commitment 
therapy; psychological flexibility
Background
Medical advances have led to increasingly prolonged illness for metastatic breast cancer 
(MBC) patients [1], with many experiencing symptoms which impair their quality of life and 
functional capacity [2–6]. Common symptoms in this population include depression, 
anxiety, sleep disturbance, pain, and fatigue [6–10]. Research indicates that 36% of MBC 
patients experience depression, anxiety, or both [7]. Worsening depression has predicted 
increased sleep problems in MBC patients [10], with over 60% reporting at least one type of 
sleep disturbance [9]. Sleep problems are frequently associated with pain and fatigue, with 
over half of MBC patients reporting clinically significant levels of these symptoms [3, 6, 
11]. Other common symptoms among cancer patients (e.g., nausea, neuropathy, swelling of 
arms and legs, hot flashes, cognitive problems) have received less attention in the MBC 
literature [6, 12–14].
Preliminary evidence suggests that symptoms may disrupt the daily activities of MBC 
patients [3, 15]. One study found that greater symptom severity and interference were 
associated with greater daily activity impairment and reduced work productivity in this 
population [3]. Another study of MBC patients found that greater depressive symptoms 
predicted increases in global perceptions of activity disruption over a 3-month period [15].
To date, intervention trials to reduce symptoms and distress have been largely ineffective for 
MBC patients [16]. According to a recent Cochrane meta-analysis [16], non-pharmacologic 
interventions for MBC patients, most of which were cognitive-behavioral or emotion-
focused group therapy, have only yielded short-term benefits with respect to pain and 
distress reduction. Cognitive-behavioral therapy is a problem-focused approach with a 
primary goal of symptom reduction. Novel intervention models seek to shift the emphasis 
from symptom reduction to decreasing symptom-related suffering and interference with 
valued activities [17]. Given that symptom-related suffering and interference are focal points 
of palliative care for advanced cancer patients [18], these novel intervention models might 
be particularly well-suited for MBC patients.
One psychological intervention that holds promise for reducing symptom-related suffering 
and functional interference in cancer patients is Acceptance and Commitment Therapy 
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(ACT) [19]. ACT promotes psychological flexibility so that internal experiences (e.g., 
thoughts, feelings, bodily sensations) do not impair patients’ ability to live a meaningful life 
[20]. Psychological flexibility is defined as the ability to fully experience the present 
moment, including thoughts and feelings, while persisting in value-based action [17]. This 
flexibility has been associated with reduced anxiety and depressive symptoms and better 
well-being in patients with common cancers [21, 22]. Conversely, psychological inflexibility 
occurs when people avoid unwanted thoughts and emotions, which often has the paradoxical 
effect of increasing distress and decreasing value-based action [17]. From an ACT 
perspective, values are patient-defined life directions (e.g., showing love, promoting justice) 
that are intrinsically reinforcing and provide a sense of meaning and purpose [17].
ACT has been successfully applied to a range of clinical disorders, including anxiety, 
depression, and posttraumatic stress disorder [23]. In addition, ACT has shown promising 
effects on psychological distress, quality of life, and self-management among patients with 
medical conditions such as diabetes and chronic pain [24, 25]. A small number of pilot 
studies—most of which were not randomized trials--have examined the efficacy of ACT in 
cancer patients [26]. However, one randomized trial with late-stage ovarian cancer patients 
found large improvement in mood and quality of life among ACT participants compared to 
those assigned to cognitive-behavioral therapy [27].
Despite the promising evidence presented above, several remaining questions need to be 
answered before investing resources into developing an ACT intervention for MBC patients. 
Most importantly, research is needed to establish links between key ACT constructs (i.e., 
activity engagement, psychological inflexibility, value obstruction, and value progress) and 
symptom burden in MBC patients. The current study aims to take this critical next step. 
Drawing upon ACT theory [17] and prior research [21, 22], we expected that patient 
subgroups with higher symptom levels would report less activity engagement, greater 
psychological inflexibility and value obstruction, and less value progress than subgroups 
with lower symptom levels.
Methods
Participants and procedures
Following institutional review board approval, MBC patients were recruited from an 
academic cancer center in the Midwestern United States between May and August 2015. 
Eligible patients were women with stage IV breast cancer who were fluent in English. 
Eligibility was confirmed via medical record review and consultation with oncologists. 
Research assistants mailed letters inviting study participation and consent forms to patients 
and called them to screen for eligibility and complete the informed consent process. Patients 
were excluded from study participation if they made three or more errors on a validated 6-
item cognitive screener that has been widely used with cancer patients [28]. Sample items 
include “What year is this?” and “What month is this?” At the time of enrollment, patients 
received a brochure that described available mental health services at the cancer center.
Of the 107 MBC patients who received mailed information about this study, 85 (79%) 
completed the screening assessment, 12 (11%) could not be reached via phone, and 10 (9%) 
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refused study participation. Primary reasons for refusal were time constraints and health 
concerns. Of those who completed screening, two were found to be ineligible, and 83 were 
eligible and consented to participate.
Eighty patients (96%) completed a standardized phone assessment consisting of the 
measures described below. Patients received a $40 gift card for their participation.
Measures
Physical and psychological symptoms—Ten common physical and psychological 
symptoms were assessed. Four-item NIH Patient Reported Outcomes Measurement 
Information System (PROMIS) measures [29, 30] were used to assess the severity of the 
following symptoms: anxiety, depressive symptoms, sleep disturbance, fatigue, and general 
cognitive concerns. In addition, a 3-item PROMIS measure of pain intensity was utilized 
[30]. For all items, respondents selected one of five response options that best described their 
symptom level during the past 7 days. These measures have undergone rigorous reliability 
and validity testing [29–31]. PROMIS measures were initially developed with cancer 
patients’ input [32], and a growing body of research has documented the measures’ 
reliability and validity for use with cancer patients, including those with advanced disease 
[33–35].
PROMIS measures of nausea, hot flashes, swelling of arms or legs, and neuropathy have yet 
to be developed. Thus, alternative measures of these symptoms were used, including 11 
questions from the Memorial Symptom Assessment Scale (MSAS) [36] to assess nausea, 
swelling of arms and legs, and neuropathy during the past week. In addition, a 3-item 
validated assessment of hot flashes during the past two weeks was used [37]. Questions for 
each of these measures first assessed the presence of a symptom (yes or no), followed by 
Likert-type scales to assess symptom frequency, severity, and distress or bother. For swelling 
and hot flashes, only severity and distress or bother were assessed.
Engagement in roles and activities—A 6-item PROMIS measure [29, 30] was utilized 
to assess engagement in roles and activities. Sample items are “I have to limit the things I do 
for fun with others” and “I have trouble doing all of my usual work (including work at 
home).” Items were rated on a scale from 5 (never) to 1 (always). Items were reverse scored 
and summed, with higher scores indicating greater engagement in roles and activities. As 
stated above, PROMIS measures have undergone extensive validation [29–31].
Psychological inflexibility—The 7-item Acceptance and Action Questionnaire-II (AAQ-
II) [38] was used to assess psychological inflexibility or difficulty pursuing effective 
behavior when having unwanted internal experiences. A sample item is “My painful 
experiences and memories make it difficult for me to live a life that I would value.” Items 
were rated on a scale from 1 (never true) to 7 (always true). The AAQ-II demonstrated good 
test-retest reliability and discriminant validity [38].
Value-based living—The Valuing Questionnaire (VQ) [39] consists of two, 5-item 
subscales assessing progress in living consistent with one’s values (VQ Progress) as well as 
obstructions to doing so during the past week (VQ Obstruction). Sample items are “I made 
Mosher et al. Page 4
Psychooncology. Author manuscript; available in PMC 2018 November 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
progress in the area of my life I care most about” and “Difficult thoughts, feelings or 
memories got in the way of what I really wanted to do.” Items were rated on a scale from 0 
(not at all true) to 6 (completely true). The measure showed evidence of good internal 
consistency reliability and concurrent validity with measures of psychological well-being 
and ACT constructs [39].
Demographic and medical information—Patients reported their demographic 
information. Age, date of diagnosis, and treatments were collected from medical records.
Statistical analysis
Data were analyzed with the Statistical Package for the Social Sciences (SPSS, Version 23.0; 
IBM Corp, Armonk, NY). Descriptive statistics were used to characterize demographic and 
medical characteristics, symptoms, and ACT variables in the present sample. 
Intercorrelations were computed among main study variables. Then a hierarchical 
agglomerative cluster analysis (Ward’s method, squared Euclidian distance) was conducted 
to determine patient clusters based on the severity of the ten symptoms. This analysis was 
performed because co-occurring symptoms have a compounding, negative effect on cancer 
patients’ functional status and quality of life [40]. Thus, patients with higher symptom 
burden were expected to show worse study outcomes compared to those with lower 
symptom burden. Differences between the clusters on demographic and medical factors 
were assessed using Chi-square tests and one-way ANOVAs followed by Tukey HSD tests. 
One-way ANOVAs and Tukey HSD tests also were performed to examine differences 
between patient clusters on the ten symptoms, activity engagement, psychological 
inflexibility, value obstruction, and value progress. Two-sided p-values of .05 were 
considered statistically significant.
Results
Preliminary analyses
Sample characteristics are found in Table 1. The sample was primarily Caucasian, married, 
and college-educated with a wide range of income. Patients were, on average, 56 years old 
and had been diagnosed with stage IV breast cancer four years previously. The majority of 
patients had received chemotherapy, radiation, hormonal therapy, and surgery.
Descriptive statistics, Cronbach’s alphas, and intercorrelations for the main study variables 
are found in Table 2. All measures showed acceptable internal consistency reliability (α 
range = .75 to .95). As expected, nearly all symptoms showed significant, negative 
associations with activity engagement. The only exceptions were nausea, neuropathy, and 
hot flashes, which were not significantly related to this outcome. A similar pattern of 
findings was obtained with respect to value obstruction, with most symptoms showing 
significant, positive associations with this outcome. Nausea, swelling of arms or legs, and 
hot flashes were the only symptoms unrelated to value obstruction. Additionally, half of the 
symptoms (i.e., nausea, fatigue, sleep disturbance, anxiety, and depressive symptoms) 
showed significant, negative associations with value progress. Finally, psychological 
inflexibility showed significant, positive associations with six of the ten symptoms (i.e., 
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pain, fatigue, sleep disturbance, cognitive concerns, anxiety, and depressive symptoms) as 
well as value obstruction. Conversely, greater psychological inflexibility was related to less 
value progress and engagement in roles and activities.
Primary analyses
A hierarchical agglomerative cluster analysis was conducted to derive participant clusters 
based on the severity of the ten symptoms. A 3-cluster solution was found. Cluster 1 was 
labeled “Low Symptoms,” as it comprised 47 people with low symptom levels across 
domains. Cluster 2 was labeled “Low-Moderate Symptoms” and comprised 14 people with 
low to moderate symptom levels across domains. Cluster 3 was labeled “Moderate-High 
Symptoms,” as 19 people reported moderate to high symptom levels across domains. No 
significant differences were found among the clusters on demographic variables (i.e., age, 
income, education, employment status, and marital status) and medical factors (i.e., surgery, 
radiation, chemotherapy, hormonal therapy, and time since diagnosis).
One-way ANOVAs revealed significant differences between clusters on ratings of the ten 
symptoms (see Table 3). Tukey’s post hoc comparisons showed that Cluster 1 frequently had 
lower symptom levels than the other clusters, and Cluster 2 had lower symptom levels than 
Cluster 3 for hot flashes and fatigue.
One-way ANOVAs also revealed significant differences between clusters on activity 
engagement, psychological inflexibility, and value obstruction (see Table 3). Tukey’s 
comparisons showed that Cluster 1 had greater activity engagement than the other clusters, 
which did not significantly differ from each other. Tukey’s comparisons also showed that 
Cluster 1 had lower levels of psychological inflexibility and value obstruction than Cluster 3. 
The three clusters did not differ from each other with respect to value progress.
Conclusions
This study is the first to identify subgroups of patients with MBC based on ratings of 
common symptoms and their associations with key ACT constructs (i.e., activity 
engagement, psychological inflexibility, value obstruction, and value progress). Results 
suggested that there were three patient subgroups: those with low symptoms, low-moderate 
symptoms, and moderate-high symptoms. Prior research with other cancer populations has 
also found heterogeneity with respect to patients’ symptom experience [40]. In this study, 
compared to patients with low symptoms, the other patient subgroups reported less activity 
engagement. Furthermore, relative to patients with low symptoms, the subgroup with 
moderate to high symptom levels reported greater psychological inflexibility (i.e., avoidance 
of unwanted internal experiences) and greater difficulty living a life consistent with their 
values. These results are largely consistent with ACT theory [17] and suggest that MBC 
patients with greater symptom burden may be more likely to avoid unwanted thoughts, 
emotions, and sensations and withdraw from valued activities and relationships. These 
patients may be targeted in future research examining ACT interventions for symptom 
interference.
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Two prior studies of patients with various cancer types and stages have linked greater 
avoidance of unwanted experiences or psychological inflexibility to worse physical and 
emotional well-being and greater psychological distress [21, 22]. The present findings 
extend this work by linking this avoidance to a variety of physical and psychological 
symptoms in a sample of advanced cancer patients. One explanation for these findings is that 
patients may cope with their high symptom burden by attempting to avoid aversive thoughts, 
feelings, and sensations. Alternatively, attempts to avoid symptoms may exacerbate them, as 
patients may not seek necessary support or may use ineffective methods of symptom control 
(e.g., excessive resting instead of engaging in meaningful activities). A third account of the 
findings is that a common unmeasured factor (e.g., emotional reactivity) may drive symptom 
perceptions and psychological inflexibility.
Another key finding of this study was that greater psychological inflexibility and higher 
symptom levels were related to reduced activity engagement and greater value obstruction. 
Similarly, a prior study of cancer patients found that greater psychological inflexibility was 
associated with less success in value-based living in certain domains (e.g., family, leisure) 
[21]. Consistent with these findings, ACT theorists have proposed that psychological 
suffering results from attempts to avoid aversive experiences, such as symptoms, which 
often lead to disengagement from valued activities [17].
Whereas value obstruction was associated with patient subgroups based on symptoms, 
progress in valued-based living was not. However, greater progress in value-based living was 
associated with lower levels of certain symptoms (e.g., fatigue, sleep disturbance, anxiety, 
and depressive symptoms), most of which were symptoms that characterize many 
psychological disorders. These findings underscore the importance of separately examining 
progress and obstructions to value-based living in MBC patients when predicting symptom 
outcomes. Future longitudinal research may examine whether value obstruction is more 
predictive of poor symptom outcomes than value progress.
The present findings have important implications for future research and clinical practice 
with MBC patients. First, our findings in combination with prior descriptive research on 
ACT constructs in cancer patients [21, 22] provide an empirical basis for examining 
interventions such as ACT that aim to improve acceptance of internal experiences and 
engagement in activities consistent with personal values. Results of one pilot trial suggest 
that ACT produces large improvement in mood and quality of life in advanced ovarian 
cancer patients [27]; thus ACT warrants investigation as an approach to reducing symptom 
interference in MBC patients. Additionally, our results point to the need to tailor 
interventions to patient characteristics. For example, if replicated, findings would suggest 
that patients in the “Low-Moderate Symptoms” and “Moderate-High Symptoms” subgroups 
may benefit from intervention to reduce the impact of their symptoms on activities. Further 
research is needed to determine whether symptomatic patients with high levels of 
psychological inflexibility benefit from acceptance-based approaches (e.g., ACT) to 
symptom interference in conjunction with standard symptom management.
Limitations of this study and directions for future research should be noted. The sample 
primarily consisted of highly educated, Caucasian patients. Future research should examine 
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the degree to which findings generalize to MBC patients with diverse socioeconomic and 
ethnic backgrounds. In addition, the cross-sectional design precluded an assessment of 
temporal relationships among variables. Longitudinal research is needed to determine 
whether ACT variables such as psychological flexibility predict symptom outcomes. Such 
research may include other variables central to ACT, such as cognitive defusion, 
mindfulness, value-based living in specific domains, and acceptance, to more fully examine 
the ACT model of symptom interference in MBC patients. Finally, certain symptoms (e.g., 
nausea) may have been unrelated to some ACT constructs in this study due to range 
restriction; larger samples are needed to ensure symptom heterogeneity for predicting 
outcomes.
Despite commonly used pharmacologic approaches to symptom management, MBC patients 
have high symptom burden that is a major source of suffering, impairment, and disability [2–
4, 6]. Standard non-pharmacologic approaches such as cognitive-behavioral therapy show 
limited evidence for reducing the symptom-related suffering of MBC patients [16]. ACT 
differs from traditional cognitive-behavioral approaches by emphasizing mindfulness, 
acceptance, and actions based on personal values. The current findings in combination with 
prior research [21, 22, 26] support investigating ACT as an intervention to reduce symptom 
interference and promote value-based living in this population.
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Table 1
Sample characteristics (N = 80)
Characteristic
Age (years)
 Mean (SD) 55.50 (11.26)
 Range 32–80
Years of education
 Mean (SD) 15.03 (2.42)
 Range 11–20
Years since the stage IV breast cancer diagnosis
 Mean (SD) 3.93 (3.64)
 Range 0.21–19.46
Ethnicity, no. (%)
 Non-Hispanic White 73 (91.3)
 Other ethnicitya 7 (8.8)
Married or partnered, no. (%) 53 (66.3)
Employed, no. (%) 24 (30.0)
Household income, no. (%)
 $0 – $30,999 17 (21.8)
 $31,000 – $50,999 18 (23.1)
 $51,000 – $99,999 26 (33.3)
 $100,000 + 17 (21.8)
Cancer treatment history, no. (%)
 Chemotherapy 69 (86.3)
 Radiation 52 (65.0)
 Hormonal therapy 68 (85.0)
 Mastectomy 53 (66.3)
 Lumpectomy 17 (21.3)
SD = standard deviation.
aAfrican American/Black, Hispanic, and other.
Psychooncology. Author manuscript; available in PMC 2018 November 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Mosher et al. Page 12
Ta
bl
e 
2
D
es
cr
ip
tiv
e 
st
at
ist
ic
s a
nd
 in
te
rc
or
re
la
tio
ns
 fo
r m
ai
n 
stu
dy
 v
ar
ia
bl
es
1
2
3
4
5
6
7
8
9
10
11
12
13
14
1
N
au
se
a
2
N
eu
ro
pa
th
y
0.
33
*
*
3
Sw
el
lin
g 
of
 a
rm
s o
r l
eg
s
0.
21
0.
30
*
*
4
H
ot
 fl
as
he
s
0.
14
−
0.
05
−
0.
21
5
Pa
in
0.
33
*
*
0.
38
*
*
0.
29
*
*
0.
19
6
Fa
tig
ue
0.
33
*
*
0.
29
*
*
0.
11
0.
26
*
0.
52
*
*
7
Sl
ee
p 
di
stu
rb
an
ce
0.
28
*
0.
15
0.
12
0.
21
0.
34
*
*
0.
50
*
*
8
Co
gn
iti
v
e 
co
n
ce
rn
s
0.
21
0.
26
*
0.
07
0.
13
0.
20
0.
64
*
*
0.
51
*
*
9
A
nx
ie
ty
0.
17
0.
19
0.
09
0.
23
*
0.
27
*
0.
52
*
*
0.
46
*
*
0.
44
*
*
10
D
ep
re
ss
iv
e 
sy
m
pt
om
s
0.
33
*
*
0.
14
0.
20
0.
08
0.
34
*
*
0.
50
*
*
0.
44
*
*
0.
39
*
*
0.
71
*
*
11
A
bi
lit
y 
to
 p
ar
tic
ip
at
e 
in
 so
ci
al
 ro
le
s a
nd
 
ac
tiv
iti
es
−
0.
21
−
0.
20
−
0.
33
*
*
−
0.
14
−
0.
52
*
*
−
0.
68
*
*
−
0.
38
*
*
−
0.
38
*
*
−
0.
38
*
*
−
0.
43
*
*
12
Ps
yc
ho
lo
gi
ca
l i
nf
le
x
ib
ili
ty
0.
18
0.
17
0.
10
0.
18
0.
24
*
0.
56
*
*
0.
50
*
*
0.
53
*
*
0.
75
*
*
0.
68
*
*
−
0.
36
*
*
13
Va
lu
e 
pr
og
re
ss
−
0.
27
*
−
0.
02
0.
06
−
0.
12
−
0.
11
−
0.
33
*
*
−
0.
31
*
*
−
0.
22
−
0.
36
*
*
−
0.
41
*
*
0.
37
*
*
−
0.
45
*
*
14
Va
lu
e 
ob
str
uc
tio
n
0.
20
0.
25
*
0.
14
0.
13
0.
28
*
0.
54
*
*
0.
42
*
*
0.
44
*
*
0.
61
*
*
0.
56
*
*
−
0.
38
*
*
0.
77
*
*
−
0.
38
*
*
M
ea
n
0.
63
1.
13
0.
46
1.
64
6.
60
11
.3
9
11
.1
0
11
.4
3
7.
33
6.
65
19
.6
0
13
.6
6
23
.1
4
6.
15
St
an
da
rd
 d
ev
ia
tio
n
0.
91
1.
19
0.
87
1.
92
2.
65
4.
31
3.
90
5.
11
3.
14
3.
20
6.
20
7.
28
5.
79
6.
19
Cr
on
ba
ch
’s
 α
0.
95
0.
89
0.
91
0.
75
0.
83
0.
92
0.
84
0.
95
0.
86
0.
90
0.
95
0.
91
0.
86
0.
86
*
p 
<
 0
.0
5.
*
*
p 
<
 0
.0
1.
Psychooncology. Author manuscript; available in PMC 2018 November 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Mosher et al. Page 13
Ta
bl
e 
3
Sy
m
pt
om
s a
nd
 A
CT
 v
ar
ia
bl
es
 b
y 
pa
rti
ci
pa
nt
 c
lu
ste
rs
Lo
w
 s
ym
pt
om
s (
L)
Lo
w
-M
od
er
at
e 
sy
m
pt
om
s (
L/
M
)
M
od
er
at
e-
H
ig
h 
sy
m
pt
om
s (
M
/H
)
F
p
(n
 
=
 4
7)
(n
 
=
 1
4)
(n
 
=
 1
9)
M
ea
n
SD
M
ea
n
SD
M
ea
n
SD
Tu
ke
y’
s p
os
t-h
oc
 c
om
pa
ri
so
ns
a
Sy
m
pt
om
N
au
se
a
0.
18
0.
47
1.
05
0.
88
1.
44
1.
11
22
.2
1
<
 .0
01
L 
< 
L/
M
.
00
1
L 
< 
M
/H
<
 .0
01
N
eu
ro
pa
th
y
0.
55
0.
82
2.
07
0.
95
1.
88
1.
29
20
.7
6
<
 .0
01
L 
< 
L/
M
 a
nd
 M
/H
<
 .0
01
Sw
el
lin
g 
of
 a
rm
s o
r l
eg
s
0.
10
0.
36
2.
04
0.
75
0.
18
0.
48
95
.2
4
<
 .0
01
L 
an
d 
M
/H
 <
 L
/M
<
 .0
01
H
ot
 fl
as
he
s
1.
35
1.
72
0.
32
0.
87
3.
32
1.
88
14
.9
7
<
 .0
01
L 
< 
M
/H
<
 .0
01
L/
M
 <
 M
/H
<
 .0
01
Pa
in
5.
21
2.
06
8.
07
1.
59
8.
95
2.
34
26
.4
8
<
 .0
01
L 
< 
L/
M
 a
nd
 M
/H
<
 .0
01
Fa
tig
ue
9.
66
3.
94
11
.8
6
2.
74
15
.3
2
3.
51
16
.2
8
<
 .0
01
L 
< 
M
/H
<
 .0
01
L/
M
 <
 M
/H
.
02
4
Sl
ee
p 
di
stu
rb
an
ce
9.
98
3.
34
11
.2
9
3.
31
13
.7
4
4.
45
7.
30
.
00
1
L 
< 
M
/H
.
00
1
Co
gn
iti
v
e 
co
n
ce
rn
s
10
.1
3
5.
03
12
.0
7
4.
71
14
.1
6
4.
62
4.
75
.
01
1
L 
< 
M
/H
.
00
9
A
nx
ie
ty
6.
30
2.
49
8.
14
3.
53
9.
26
3.
35
7.
73
.
00
1
Psychooncology. Author manuscript; available in PMC 2018 November 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Mosher et al. Page 14
Lo
w
 s
ym
pt
om
s (
L)
Lo
w
-M
od
er
at
e 
sy
m
pt
om
s (
L/
M
)
M
od
er
at
e-
H
ig
h 
sy
m
pt
om
s (
M
/H
)
F
p
(n
 
=
 4
7)
(n
 
=
 1
4)
(n
 
=
 1
9)
M
ea
n
SD
M
ea
n
SD
M
ea
n
SD
Tu
ke
y’
s p
os
t-h
oc
 c
om
pa
ri
so
ns
a
L 
< 
M
/H
.
00
1
D
ep
re
ss
iv
e 
sy
m
pt
om
s
5.
43
1.
81
8.
43
4.
07
8.
37
3.
88
10
.3
2
<
 .0
01
L 
< 
L/
M
.
00
3
L 
< 
M
/H
.
00
1
A
CT
 v
ar
ia
bl
e
A
bi
lit
y 
to
 p
ar
tic
ip
at
e 
in
 so
ci
al
 ro
le
s a
nd
 a
ct
iv
iti
es
21
.7
9
6.
31
16
.3
6
3.
67
16
.5
8
5.
19
8.
42
<
 .0
01
L 
> 
L/
M
.
00
7
L 
> 
M
/H
.
00
3
Ps
yc
ho
lo
gi
ca
l i
nf
le
x
ib
ili
ty
11
.2
1
5.
30
15
.9
3
6.
55
18
.0
5
9.
50
7.
99
.
00
1
L 
< 
M
/H
.
00
1
Va
lu
e 
pr
og
re
ss
24
.0
0
5.
47
22
.9
3
4.
50
21
.2
1
7.
08
1.
59
.
21
0
Va
lu
e 
ob
str
uc
tio
n
4.
28
4.
56
7.
86
5.
33
9.
53
8.
42
6.
25
.
00
3
L 
< 
M
/H
.
00
4
a O
nl
y 
sig
ni
fic
an
t T
u
ke
y 
co
m
pa
ris
on
s a
re
 re
po
rte
d.
 S
D
 =
 st
an
da
rd
 d
ev
ia
tio
n.
 A
CT
 =
 A
cc
ep
ta
nc
e 
an
d 
Co
m
m
itm
en
t T
he
ra
py
.
Psychooncology. Author manuscript; available in PMC 2018 November 01.
